Discussion
myocyte loss
AMI, DILATED CARDIOMYOPATHY
The present study revealed that two post-AMI intracoronary MSC infusions could significantly improve LVEF on both CMR imaging and echocardiography. Compared to the control group, single MSC transplantation improved the EF by 4.54 ± 2%, and repeated intervention did so by 7.45 ± 2% when measured by CMR imaging (Currently, post-AMI therapeutic measures seek to avert cardiac remodeling and myocyte loss [One issue with cardiac stem cell therapy is the type of cell used. A Cochrane meta-analysis showed that treating AMI patients with a reduced LVEF with BM-MNCs effectively increases LVEF, yielding survival and functional benefits in patients below 55 with an EF below 37% [The route of stem cell injection has also been a subject of study. In an animal study, Gong et al. showed that a repeated intravenous dose of human umbilical cord-derived MSCs had a superior therapeutic effect than single-dose treatment in improving the LV function of rats with dilated cardiomyopathy [The timing of delivery of stem cells for following an AMI is a crucial therapeutic parameter. Numerous trials [Regarding the number of MSCs used, the current understanding is that the optimal number is 10The literature does not support the theory of differentiation into cardiomyocytes as the mechanisms behind the therapeutic effects of stem cells on post-AMI heart, as the number of cells required to account for such effects is immense [This study had some limitations. Firstly, while we originally planned to conduct a sham procedure as a placebo treatment for the control group [